Directorio

We are doing this study to find out if an experimental technology called the HBDx Small RNA Diagnostic Test for Lung Cancer can help diagnose people with lung cancer early.

We are doing this study to identify patients who have gene changes or mutations in their tumor(s) and might be eligible for treatment using a combination of targeted therapy options. This study is called ComboMATCH (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice).

We are doing this study to find out if a study drug called binimetinib is a safe and effective option for cancers that harbor certain genetic mutations (RAS/RAF/MEK). We want to know how well it works on its own for some cancers, and how it works in combination with another study drug called palbociclib for other cancers.

We are doing this study to compare the outcomes for women who use selumetinib alone and women who use selumetinib plus olaparib to treat endometrial or ovarian cancer. We want to know which option is better for women whose tumors harbor a mutation in a key survival pathway called KRAS.

We are doing this study to find out if combining a drug called ipatasertib with the chemotherapy drug paclitaxel can help shrink or control solid tumors that have AKT gene mutations.

We are doing this study to find out if a drug called pembrolizumab (the study drug) is a safe and effective option for people with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. We want to know if adding it to treatment with the usual drug for this type of cancer can improve results.

We are doing this study to find out if a new vaccine (ESR1 peptides) is safe and if they will help people with estrogen receptor positive (ER+) breast cancer.

We are doing this study to keep tabs on the performance of a medical device called TVT Exact. This device is used to help control stress urinary incontinence. We want to know how well this device works long-term in Duke patients who elected to use it.